• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Incannex Healthcare Inc.

    5/15/25 7:05:03 PM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IXHL alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Incannex Healthcare Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    45333L106

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    45333L106


    1Names of Reporting Persons

    S.H.N. Financial Investments Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    ISRAEL
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    FI


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Incannex Healthcare Inc.
    (b)Address of issuer's principal executive offices:

    Suite 105, 8 Century Circuit, Norwest, NSW 2153, Australia
    Item 2. 
    (a)Name of person filing:

    S.H.N. Financial Investments Ltd.
    (b)Address or principal business office or, if none, residence:

    Herzliya Hills Arik Einstein 3, Israel, 4610301
    (c)Citizenship:

    Israel
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    45333L106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    0 This amendment refers to a Schedule 13G filed with the Securities and Exchange Commission on March 14, 2025, covering 1,929,015 shares of Common Stock purchased on March 10, 2025. Nir Shamir is the Chief Executive Officer of the Reporting Person. As such, Mr. Shamir may be deemed to beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the securities described herein. To the extent Mr. Shamir is deemed to beneficially own such securities, Mr. Shamir disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 13 and the rules thereunder.
    (b)Percent of class:

    0  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    S.H.N. Financial Investments Ltd.
     
    Signature:/s/ Nir Shamir
    Name/Title:Nir Shamir, Chief Executive Officer
    Date:05/15/2025
    Get the next $IXHL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IXHL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IXHL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Incannex Announces Reverse Stock Split

    MELBOURNE, Australia and NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage pharmaceutical company developing innovative combination therapies for high-impact medical conditions, today announced that the board of directors of the Company approved a 1-for-30 reverse stock split (the "Reverse Split") of the Company's common stock. The Reverse Split was approved by the stockholders of the Company at a special meeting of the Company held on May 27, 2025. The Reverse Split will legally take effect at 4:01 p.m. Eastern Time, on February 26, 2026. The Company's common stock will open for trading under a new CUSIP numb

    2/25/26 9:20:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board

    MELBOURNE, Australia and NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced the appointment of three additional members to its recently established Clinical Advisory Board ("CAB"): Murray B. Stein, MD, MPH; Andrew Cutler, MD; and Amir Kalali, MD. The CAB was formed to provide independent clinical and scientific guidance as the Company progresses PSX-001 into its next phase of clinical and regulatory development. The addition of Drs. Stein, Cutler, and Kalali further strengthens the Board's expertise across psychiatry, neurobiology, psychopharmacology, an

    1/29/26 8:00:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Incannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 Program

    MELBOURNE, Australia and NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, announces the formation of a Clinical Advisory Board (CAB) to support the continued advancement of its PSX-001 development program in generalized anxiety disorder. The newly established CAB has been formed to provide independent clinical and scientific guidance as the Company progresses PSX-001 into its next phase of clinical and regulatory development. The CAB gathers leading experts in psychiatry, neurobiology, and psychopharmacology, strengthening the scientific rigor and patient-focused appr

    1/22/26 8:00:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IXHL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Valentine Troy was granted 11,302,608 shares, increasing direct ownership by 1,616% to 12,001,858 units (SEC Form 4)

    4 - Incannex Healthcare Inc. (0001873875) (Issuer)

    11/14/25 6:18:24 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Clark Robert was granted 1,686,956 shares, increasing direct ownership by 1,687% to 1,786,956 units (SEC Form 4)

    4 - Incannex Healthcare Inc. (0001873875) (Issuer)

    11/14/25 6:17:03 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Widdows Peter was granted 1,686,956 shares, increasing direct ownership by 623% to 1,957,803 units (SEC Form 4)

    4 - Incannex Healthcare Inc. (0001873875) (Issuer)

    11/14/25 6:15:28 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IXHL
    SEC Filings

    View All

    Incannex Healthcare Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - Incannex Healthcare Inc. (0001873875) (Filer)

    2/25/26 8:00:33 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Incannex Healthcare Inc.

    10-Q - Incannex Healthcare Inc. (0001873875) (Filer)

    2/13/26 7:48:45 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Incannex Healthcare Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Incannex Healthcare Inc. (0001873875) (Filer)

    1/29/26 8:04:16 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IXHL
    Leadership Updates

    Live Leadership Updates

    View All

    Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board

    MELBOURNE, Australia and NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today announced the appointment of three additional members to its recently established Clinical Advisory Board ("CAB"): Murray B. Stein, MD, MPH; Andrew Cutler, MD; and Amir Kalali, MD. The CAB was formed to provide independent clinical and scientific guidance as the Company progresses PSX-001 into its next phase of clinical and regulatory development. The addition of Drs. Stein, Cutler, and Kalali further strengthens the Board's expertise across psychiatry, neurobiology, psychopharmacology, an

    1/29/26 8:00:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo

    NEW YORK and MELBOURNE, Australia, July 25, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces the appointment of Charlene E. Gamaldo, M.D. to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board. Incannex Chief Medical Officer Dr. Lou Barbato commented:"We are fortunate to welcome Dr. Gamaldo to the Incannex Clinical Advisory Board. Her leadership across neurology, psychiatry, and public health, combined with a distinguished track record in sleep medicine, brings tremendous value to our obstructive sleep apnea prog

    7/25/25 7:30:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch

    NEW YORK and MELBOURNE, Australia, June 24, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces the appointment of Douglas B. Kirsch, M.D., FAAN, FAASM to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board. "We are honored to welcome Dr. Kirsch to the IHL-42X Clinical Advisory Board," stated Dr. Lou Barbato, Incannex Chief Medical Officer. "His extensive clinical experience and leadership within the sleep medicine community will be instrumental as we advance IHL-42X through late-stage development. With his additi

    6/24/25 7:30:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IXHL
    Financials

    Live finance-specific insights

    View All

    Incannex Healthcare Quarterly Activities Report and Appendix 4C Cash Flow Statement

    MELBOURNE, Australia, July 27, 2022 /PRNewswire/ -- Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL) (NASDAQ:IXHL), ('Incannex' or the 'Company'), is pleased to provide its quarterly activities report and appendix 4C for the period ended 30 June 2022. Incannex is undertaking a multitude of U.S. Food and Drug Administration ('FDA') programs for cannabinoid pharmaceutical products and psychedelic medicine therapies administered by health professionals. Cannabinoid IHL-42X: positive phase 2a clinical trial results in patients with obstructive sleep apnoea In June 2022, Incannex announced positive results from full analysis of its phase 2 clinical trial o

    7/27/22 7:55:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quarterly Activities Report and Appendix 4C Cash Flow Statement

    Highlights: Positive phase 2a clinical trial results for IHL-42X with 60% of trial participants experiencing at least a 55% reduction in the Apnoea Hypopnea Index ('AHI') 20% of IHL-42X clinical trial participants experienced a reduction in AHI of greater than 80% completes comprehensive in vivo study on the neuroprotective capability of IHL-216A with results being analysed to be released within 2-3 weeks treatment commences in the phase 2a clinical trial to assess psilocybin and specialised psychotherapy for the treatment of generalised anxiety disorder initiates a second clinical psychedelic therapy program in a leading-edge academic field of virtual reality (VR) exposure response therapy

    4/28/22 7:55:00 AM ET
    $IXHL
    Biotechnology: Pharmaceutical Preparations
    Health Care